Brian O Mahony/X
Apr 26, 2026, 11:55
Brian O Mahony: Pierce Highlights Unique Inhibitor Cases in AAV-ET3 FVIII Gene Therapy Trial
Brian O Mahony, CEO of Irish Haemophilia Society, Former President of WFH and EHC, shared a post on X:
”Pierce on Gene Therapy safety WFH Congress 2026 AAV-ET3 FVIII Human Porcine hybrid Gene Therapy trial in US.
Both participamts developed inhibitors.
These are the only inhibitors seen to date in all the haemophilia clinical trials.”
Stay updated with Hemostasis Today.
-
May 18, 2026, 13:29Brian O Mahony: Ahead of the World Health Assembly in Geneva
-
May 18, 2026, 13:24Marian Galovic: When, Why and How to Perform an EEG After Stroke?
-
May 18, 2026, 13:23Behnood Bikdeli: A Wonderful Experience at the International Symposium on Thrombosis and Vessels
-
May 18, 2026, 13:16Wolfgang Miesbach: New Editorial Highlights – 6 Year Outcomes of Hemophilia B Gene Therapy
-
May 18, 2026, 13:10Ritika Jankar: Hemophilia Market Size to Reach USD 23.46 Billion by 2035
-
May 18, 2026, 13:10Natasha Kazi: Early Anticoagulation Linked to Better Outcomes in Acute PE
-
May 18, 2026, 13:02Paris Margaritis: Native Cellular Biology and the Future of Durable Hemophilia A Gene Therapy
-
May 18, 2026, 12:48Ilenia Calcaterra: Impact of Pain on Severe Haemophilia A Patients Receiving Emicizumab Prophylaxis
-
May 18, 2026, 08:12Perioperative Anticoagulation Management Isn’t a Checklist – Thrombosis Canada